# PTN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/PTN) · [Earnings tab](https://www.lopjlb.com/stock/PTN?tab=earnings) Updated: 2026-09-02T06:29:34 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of CallCards Palatin’s story shifts from a cash‑constrained, pre‑revenue biotech with a broad melanocortin pipeline to a company that has raised equity, secured collaboration revenue and narrowed its focus on MC4R‑based obesity candidates. Early quarters emphasized Phase 3 readouts for PL9643 and multiple MC1R/MC4R programs while warning of regulatory, manufacturing and runway risks. The sale of Vyleesi removed product revenue but freed cash, prompting a succession of funding actions – equity raises, public offerings and ATM proceeds – that temporarily bolstered the balance sheet. Clinical progress accelerated: PL9643 Phase 3 results, BMP‑801 (BMT‑801) Phase 2 delivery, PL‑7737 orphan designation and IND filings, and a retinal partnership with Boehringer. Simultaneously, the company faced a NYSE delisting, persistent cash‑runway concerns, and heightened safety questions around GI effects and hyperpigmentation. By Q1‑2026 the firm posted net income from collaborations and an $18.2 M raise, yet later quarters flagged limited cash beyond 2027 and the discontinuation of PL‑7737. Overall, Palatin moves from broad exploratory work toward a tighter obesity‑centric portfolio, but regulatory, funding and safety risks remain recurring themes. ## Latest CallCard · Q3 Palatin reported Q3 2026 revenue of $3.9M, narrowed loss to $1.4M, and said its peptide MC4R agonist is on track for a Q4 IND while the oral program aims for an IND in H1 2027. **Guidance:** maintained — Management reaffirmed cash runway through June 30 2027 with no change to prior guidance. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2 Prepared remarks emphasized on‑track IND submission for peptide in Q4 2026 and confidence in pipeline progress. ### Demand visibility Strong unmet need for rare obesity disorders. Patients with hypothalamic obesity, Prader‑Willi and Bardet‑Biedl syndromes require lifelong therapy; current options have tolerability issues. ### Capital allocation Advancing pipeline using collaboration and licensing revenue. Received $3.8M upfront from Altanispac and €7.5M from Boehringer Ingelheim, supporting cash resources. ### Milestones - **Peptide MC4R agonist** [on_track]: Targeting IND submission in Q4 2026. - **Oral small‑molecule MC4R agonist** [at_risk]: Aim for IND in H1 2027; timeline discussed as potentially delayed. - **Boehringer Ingelheim retinal partnership** [delivered]: Upfront and milestone payments totaling €7.5M received in H2 2025. - **Altanispac PL‑9643 sublicensing** [delivered]: $3.8M upfront consideration received Jan 2026. - **PL‑8177 ulcerative colitis program** [new]: Positioned for potential partnering after positive Phase II results. - **PL‑7737 program** [delayed]: Discontinued due to insufficient selectivity. - **Next‑generation oral candidates** [new]: Advancing compounds with improved selectivity; IND target H1 2027. - **IND‑enabling studies for peptide** [on_track]: Studies underway, keeping schedule for Q4 IND. ### Fears / risks - **Competitive landscape**: Risk of being several years behind Rhythm's approved setmelanotide. - **Regulatory risk**: Potential delays in IND filing for the oral small‑molecule program. - **Funding risk**: Reliance on milestone payments and collaboration revenue to fund operations. - **Safety risk**: Residual MC1R activity could cause hyperpigmentation side effects. - **Commercial risk**: Need to demonstrate superior tolerability and usability to gain market adoption. - **Development risk**: Final candidate selection for oral program remains pending, creating timeline uncertainty. ### Key quotes > “Net loss for the third quarter of fiscal 2026 was $1.4 million or $0.37 per basic and diluted common share compared to a net loss of $4.8 million or $9.13 per basic and diluted common share for the prior year period.” ## Quarter one-liners - **2026 Q3:** Palatin reported Q3 2026 revenue of $3.9M, narrowed loss to $1.4M, and said its peptide MC4R agonist is on track for a Q4 IND while the oral program aims for an IND in H1 2027. - **2026 Q2:** Palatin strengthened its balance sheet, advanced its MC4R obesity pipeline with on‑track IND filings, and highlighted cash runway beyond March 2027 while fielding analyst questions on safety and differentiation. - **2026 Q1:** Palatin posted a strong Q1 FY2026 with $8.8M collaboration revenue, net income of $4.7M, an $18.2M equity raise, and announced IND‑filing targets for its obesity candidates in H1 2026 while highlighting a lucrative Boehringer retinal partnership. - **2025 Q3:** Palatin reports Q3 FY25 with $2.5M cash (plus $3.5M post-quarter), NYSE delisting, positive Phase 2 obesity data (Bremelanotide+Tirzepatide), PL7737 orphan status, PL-8177 UC and PL-9643 dry eye data, seeking partnerships and financing. - **2025 Q2:** Palatin reported Q2 FY2025 with no product revenue post-Vyleesi sale, $3.4M cash, upcoming obesity signal detection data, and strategic focus on MC4R assets for obesity and rare diseases. - **2025 Q1:** — - **2024 Q4:** Palatin sold Vyleesi for $171M, retains obesity rights; PL9643 dry eye Phase III positive, FDA aligned for NDA H1 2026; MCR4 obesity Phase II with tirzepatide enrolling, data Q1 2025; cash $9.5M, seeking funding. - **2024 Q3:** Palatin reported no product sales this quarter, highlighted positive Phase 3 results for PL9643 dry‑eye therapy, outlined multiple Melanocortin programs with data readouts slated for mid‑2024, and said its cash will fund operations into H2 2024. ## Theme arcs - **Cash runway** (deteriorating): Cash fell from $10 M (2024 Q3) to $2.5 M (2025 Q3), briefly boosted by an $18.2 M raise (2026 Q1) but again low by 2026 Q3 - **Funding strategy** (improving): Progressed from seeking funding (2024 Q4) to equity raise, public offering and ATM proceeds (2026 Q1‑Q2) - **Clinical progress** (improving): Multiple Phase 2/3 milestones delivered, IND filings initiated, and retinal collaboration revenue generated - **Regulatory risk** (stable): Consistent concerns about FDA endpoint selection, IND acceptance and manufacturing guidance - **Market demand visibility** (stable): No product revenue after Vyleesi sale; demand remains unproven for pipeline - **Listing status** (deteriorating): Delisted from NYSE American in 2025 Q3, now OTC Pink - **Partnerships & collaborations** (improving): Boehringer Ingelheim retinal deal delivered upfront and milestone payments - **Obesity pipeline focus** (new): Shift toward MC4R peptide and oral agonists starting 2025 Q2 ## Guidance path 2024 Q3:maintained → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2026 Q1:maintained → 2026 Q2:maintained → 2026 Q3:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/PTN`